• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Immunotherapy Evolution Continues with Innovative Approaches to Multiple Myeloma Treatment

by | Sep 28, 2024 | Myeloma News

Source: Pharmacy Times articles Experts discuss emerging targets in the immunotherapy landscape and how to improve patient outcomes through innovative approaches. Read More

Isatuximab-Lenalidomide Demonstrates Strong Efficacy, Tolerability in Smoldering Multiple Myeloma

by | Sep 28, 2024 | Myeloma News

Source: Pharmacy Times articles These interim trial results support the ongoing phase 3 ITHACA trial. Read More

AURIGA Results Support Addition of Daratumumab in Maintenance Setting for Myeloma

by | Sep 28, 2024 | Myeloma News

Source: Pharmacy Times articles Ashraf Badros, MBCHB, discussed new data from the AURIGA study presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil. Read More

Overcoming Treatment Challenges in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapy

by | Sep 27, 2024 | Myeloma News

Source: Pharmacy Times articles Experts discuss immunotherapy advancements and challenges of resistance, efficacy, and toxicity in patient management. Read More

Latest CARTITUDE-4 Data Highlight the Benefits of Cilta-Cel in Multiple Myeloma

by | Sep 27, 2024 | Myeloma News

Source: Pharmacy Times articles The trial is evaluating ciltacabtagene autoleucel (cilta-cel, Carvykti; Johnson & Johnson) in patients with relapsed and lenalidomide-refractory multiple myeloma. Read More

Talquetamab-Daratumumab-Pomalidomide Combination Led to Durable Response in Patients With Relapsed/Refractory Multiple Myeloma

by | Sep 27, 2024 | Myeloma News

Source: Pharmacy Times articles Promising depth of response and consistent safety profile support the use of talquetamab as a combination agent. Read More
« Older Entries
Next Entries »

Recent Content

  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT